These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24920577)

  • 41. Direct disease-inducing effects of menthol through the eyes of tobacco companies.
    Salgado MV; Glantz SA
    Tob Control; 2011 May; 20 Suppl 2(Suppl_2):ii44-8. PubMed ID: 21504931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Creating demand for foreign brands in a 'home run' market: tobacco company tactics in South Korea following market liberalisation.
    Lee S; Lee K; Holden C
    Tob Control; 2014 May; 23(3):e8. PubMed ID: 23152099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. British American Tobacco's tactics during China's accession to the World Trade Organization.
    Zhong F; Yano E
    Tob Control; 2007 Apr; 16(2):133-7. PubMed ID: 17400952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tobacco industry strategies for flavour capsule cigarettes: analysis of patents and internal industry documents.
    van der Eijk Y; Teo KW; Tan GPP; Chua WM
    Tob Control; 2023 Apr; 32(e1):e53-e61. PubMed ID: 34611048
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tobacco manufacturers' defence against plaintiffs' claims of cancer causation: throwing mud at the wall and hoping some of it will stick.
    Milberger S; Davis RM; Douglas CE; Beasley JK; Burns D; Houston T; Shopland D
    Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv17-26. PubMed ID: 17130620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Open doorway to truth: legacy of the Minnesota tobacco trial.
    Hurt RD; Ebbert JO; Muggli ME; Lockhart NJ; Robertson CR
    Mayo Clin Proc; 2009 May; 84(5):446-56. PubMed ID: 19411441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Marketing with tobacco pack onserts: a qualitative analysis of tobacco industry documents.
    Apollonio DE; Glantz SA
    Tob Control; 2019 May; 28(3):274-281. PubMed ID: 29954860
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reinforcement of smoking and drinking: tobacco marketing strategies linked with alcohol in the United States.
    Jiang N; Ling PM
    Am J Public Health; 2011 Oct; 101(10):1942-54. PubMed ID: 21852637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of public law-based litigation in tobacco companies' strategies in high-income, FCTC ratifying countries, 2004-14.
    Steele SL; Gilmore AB; McKee M; Stuckler D
    J Public Health (Oxf); 2016 Sep; 38(3):516-521. PubMed ID: 26036703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. "We think globally": the rise of Paraguay's Tabacalera del Este as a threat to global tobacco control.
    Gomis B; Lee K; Carrillo Botero N; Shepherd P; Iglesias RM
    Global Health; 2018 Nov; 14(1):110. PubMed ID: 30454045
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents.
    Ferris Wayne G; Connolly GN; Henningfield JE
    Tob Control; 2006 Jun; 15(3):189-98. PubMed ID: 16728749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tobacco industry tactics for resisting public policy on health.
    Saloojee Y; Dagli E
    Bull World Health Organ; 2000; 78(7):902-10. PubMed ID: 10994263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Asian herbal-tobacco cigarettes: "not medicine but less harmful"?
    Chen A; Glantz S; Tong E
    Tob Control; 2007 Apr; 16(2):e3. PubMed ID: 17400933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Menthol: putting the pieces together.
    Lee YO; Glantz SA
    Tob Control; 2011 May; 20 Suppl 2(Suppl_2):ii1-7. PubMed ID: 21504926
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imitating waterpipe: Another tobacco industry attempt to create a cigarette that seems safer.
    Ahmad I; Dutra LM
    Addict Behav; 2019 Apr; 91():244-252. PubMed ID: 30366727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Invisible smoke: third-party endorsement and the resurrection of heat-not-burn tobacco products.
    Elias J; Ling PM
    Tob Control; 2018 Nov; 27(Suppl 1):s96-s101. PubMed ID: 29875153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health preemption behind closed doors: trade agreements and fast-track authority.
    Crosbie E; Gonzalez M; Glantz SA
    Am J Public Health; 2014 Sep; 104(9):e7-e13. PubMed ID: 25033124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The intractable cigarette 'filter problem'.
    Harris B
    Tob Control; 2011 May; 20 Suppl 1(Suppl_1):i10-6. PubMed ID: 21504917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmaceuticalisation as the tobacco industry's endgame.
    Hendlin YH; Han EL; Ling PM
    BMJ Glob Health; 2024 Feb; 9(2):. PubMed ID: 38316465
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Application of Philip Morris' Litigation Prevention Program in South Korea.
    Kim JH; Kim J; Lee S
    Asia Pac J Public Health; 2021; 33(2-3):188-195. PubMed ID: 33383993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.